---
title: 'Associate Medical Director, Clinical Development at Tonix Pharmaceuticals'
canonical: 'https://feeny.ai/job/associate-medical-director-clinical-development-tonix-pharmaceuticals-berkeley-pa6mx85qwvws'
type: 'job'
last_seen: '2026-09-09'
---

# Associate Medical Director, Clinical Development at Tonix Pharmaceuticals 

- **Company:** Tonix Pharmaceuticals 
- **Location:** Berkeley Heights, NJ
- **Compensation:** $180k–$240k
- **Posted:** 2026-08-27
- **Last confirmed live:** 2026-09-09
- **Apply:** https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4384197009

## Job description

Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti-Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit [www.tonixpharma.com](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D9p5FBvlzG2u-9NzVEDdUgRNdl57Mw08p4h9XviYYnbwVJ-X_DNEOeN4RdGA64IhTnk9R4lQWNXhq0g8TrvoRTCZSpqmowBapMZCbqP_sxm0%3D&data=05%7C02%7Cmarsha.ihrig%40tonixpharma.com%7C016ba434378242bb501908dea48d8908%7C9f3c9f8851ca4393815e405a5f206a29%7C0%7C0%7C639129124987080441%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=WrmW8ZuY9XRYJZM0BMPu3thoab5uVHnt9SqBNHIoDuU%3D&reserved=0) and follow the Company on [LinkedIn](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DbldblPUeLBo2VtrimIDsthVk4RaPH1sCjnDw18J2Q9UGKOYpi7kKsd6NuJ4rb7a1ocGevguAt4l_8t8TE5rfCP1YmSBTJO1HR9Uo9KAv_DEwtbEkJhm1CdLRAEbAUNB-&data=05%7C02%7Cmarsha.ihrig%40tonixpharma.com%7C016ba434378242bb501908dea48d8908%7C9f3c9f8851ca4393815e405a5f206a29%7C0%7C0%7C639129124987109283%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=dHRzyv5dfKFOhCroh809txjNcJOjNrBSQRyfSgHaIu8%3D&reserved=0) and [X](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D0NgIEJjy96AytWlfgCqgqVv5cOeUVkGOTFS78koSy22XXOczOtXjxSorNUcN-uDTk4CYVQkJndgCk6o2RQBlKQ%3D%3D&data=05%7C02%7Cmarsha.ihrig%40tonixpharma.com%7C016ba434378242bb501908dea48d8908%7C9f3c9f8851ca4393815e405a5f206a29%7C0%7C0%7C639129124987130654%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=frLcoK5ETOWzJq9lmvkirCS8HaHc2WCX%2Fg4ESMSdLgk%3D&reserved=0).

*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Position Overview

The Associate Medical Director, Clinical Development will play a key role in advancing clinical programs by contributing to clinical strategy, study design and execution, data interpretation, and development of clinical and regulatory documents. Working cross-functionally with Clinical Operations, Biostatistics, Regulatory Affairs, Pharmacovigilance, and other teams, this individual will help translate scientific insights into strong clinical evidence and meaningful program decisions.

This individual contributor role offers significant ownership and the opportunity to influence clinical development strategy while working closely with cross-functional leaders.

Essential Functions

- Provide scientific leadership for and contribute to the clinical development strategy and plans for vaccine and prophylactic monoclonal antibody candidates from early-stage development through later-stage clinical studies.
- Lead and support the design, implementation, execution, and interpretation of Phase 1–3 clinical trials, as applicable.
- Author clinical study protocols, protocol amendments, informed consent materials, clinical study reports, investigator brochures, statistical analysis plans, and other clinical and regulatory documents.
- Provide scientific input into study objectives, endpoints, eligibility criteria, schedules of assessments, immunogenicity evaluations, and exploratory biomarker strategies.
- Review emerging clinical data to evaluate safety, tolerability, immunogenicity, efficacy, and overall benefit-risk.
- Lead ongoing medical and scientific data review, including review of listings, tables, figures, laboratory results, adverse events, protocol deviations, and other clinical trial data.
- Partner closely with Biostatistics and Data Management on data analysis, interpretation, and presentation.
- Work with Clinical Operations to support high-quality study execution, including investigator and site engagement, study training, enrollment strategies, and resolution of scientific or clinical study issues.
- Conduct field assessments of clinical trial progress, including travel to investigative sites and endemic areas, as needed, to evaluate study execution, patient populations, and enrollment of appropriate high-risk populations.
- Collaborate with laboratory partners on immunologic assays and interpretation of humoral and cellular immune-response data, as appropriate to the program.
- Contribute to regulatory submissions and interactions with regulatory authorities, including briefing documents, responses to information requests, and clinical sections of INDs/BLAs or other applicable submissions.
- Support preparation of abstracts, posters, presentations, manuscripts, and other scientific communications describing clinical program results.
- Monitor relevant scientific literature, competitive programs, regulatory guidance, epidemiology, and advances in vaccinology and infectious diseases.
- Develop effective relationships with investigators, key opinion leaders, external experts, CROs, laboratories, and other development partners.
- Contribute to cross-functional program and study teams and communicate clinical findings, risks, and recommendations clearly to internal stakeholders.
- Serve as a clinical development scientific lead for assigned studies or programs, integrating clinical, operational, statistical, safety, and regulatory perspectives to support program-level decision-making.
- Maintain high standards of scientific rigor, data integrity, GCP compliance, and patient safety.

Necessary Skills and Abilities

- Strong scientific foundation in vaccinology, immunology, infectious diseases, or a related scientific or medical discipline.
- Ability to critically analyze complex clinical and scientific datasets and translate findings into clear conclusions and recommendations.
- Excellent organizational skills with the ability to manage multiple priorities and deliver high-quality work within timelines.
- Strong interpersonal and collaboration skills, with the ability to work effectively across scientific, clinical, operational, and regulatory functions.
- Comfortable operating in a fast-paced biopharmaceutical environment, with the ability to roll up your sleeves, work hands-on, and adapt as priorities evolve
- High attention to detail, intellectual curiosity, sound scientific judgment, and commitment to patients and rigorous clinical research.
- Willingness and ability to travel up to 20% to clinical trial sites and endemic areas to assess study progress, engage with investigators and site teams, and provide clinical and scientific insight to support enrollment of appropriate high-risk patient populations.

Educational Requirements

- PhD, PharmD, MD, or equivalent advanced degree in a relevant scientific or medical discipline required. MD preferred but not required.

## Experience Requirements

- 5+ years of relevant clinical development experience within the biotechnology or pharmaceutical industry.
- Demonstrated clinical development experience, including direct experience supporting vaccine clinical development.
- Experience leading and providing scientific oversight for clinical trials, including study design, execution, data review, and interpretation.
- Strong understanding of clinical endpoints, statistical concepts, and benefit-risk assessment, with experience applying these principles to large clinical trials.
- Experience with vaccine, infectious disease, and/or prophylactic monoclonal antibody clinical development preferred.
- Experience reviewing and interpreting clinical datasets and contributing to clinical protocols, study reports, regulatory documents, publications, or presentations.
- Strong understanding of clinical trial methodology, GCP, and the drug/biologic development process.
- Experience working on cross-functional clinical development teams.
- Familiarity with immunogenicity assessments, including antibody and/or cellular immune-response measurements, preferred.

Salary Range $180,000—$240,000 USD

*Please note that Tonix does not offer sponsorship for this role.

Recruitment & Staffing Agencies

Tonix does not accept agency resumes unless contacted directly by internal Tonix Talent Acquisition. Please do not forward resumes to Tonix employees or any other company location; Tonix is not responsible for any fees related to unsolicited resumes.

## Compensation & Benefits

Tonix provides a comprehensive compensation and benefits package which includes:

- Medical, Dental & Vision Insurance, Basic and Voluntary Life and AD&D Insurance, Short- and Long-Term Disability Insurance, Flexible Spending Accounts, Health Savings Account, and Employee Assistance Programs
- Pet Insurance
- Retirement Savings 401k with company match and annual discretionary stock options
- Generous Paid Time Off, Sick Time, & Paid Holidays
- Career Development and Training

Tonix provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, sex, national origin, age, genetics, or any other characteristic protected by law.  In addition to federal law requirements, Tonix complies with applicable state and local laws governing nondiscrimination in employment.  This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfers, leaves of absence, compensation, and training.  Tonix expressly prohibits any form of workplace harassment based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin, age, genetic, information, disability, veteran status, or any other characteristic protected by law.

## About Tonix Pharmaceuticals 

## Company Overview
- **One-liner**: A fully-integrated biopharmaceutical company commercializing and developing innovative therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases.
- **Entity Type**: Public (NASDAQ: TNXP)
- **Headquarters**: Berkeley Heights, New Jersey, United States (as indicated by zip code 07922 on the investor relations page) [ir.tonixpharma.com](https://ir.tonixpharma.com/)
- **Founded**: Not publicly available from provided sources
- **Founders**: Not publicly available from provided sources

## Core Business
- **Primary industry/industries**: Biotechnology / Pharmaceuticals (therapeutics)
- **Target customers**: B2B – physicians (rheumatology, primary care, pain management, neurology), hospitals, specialty distributors, and patients through prescription-based access.
- **Mission or purpose statement**: “We listen, we develop, we deliver – so that patients feel seen, heard, and empowered to live fully again.” [tonixpharma.com](https://www.tonixpharma.com/)

## Products & Services
- **TONMYA® (cyclobenzaprine HCl sublingual tablets)**: Approved in the U.S. (August 2025) and launched in November 2025 for the treatment of fibromyalgia in adults – the first new medicine for fibromyalgia in over 15 years. Non-opioid, centrally acting analgesic designed for bedtime dosing. [tonixpharma.com](https://www.tonixpharma.com/)
- **Zembrace® SymTouch® (sumatriptan injection)**: FDA-approved prescription product for the treatment of acute migraine. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **Tosymra® (sumatriptan nasal spray)**: FDA-approved prescription product for acute migraine. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-102 SL (cyclobenzaprine HCl sublingual tablets)**: Investigational for Major Depressive Disorder (Phase 2 planned mid-2026) and Acute Stress Disorder/Reaction (Phase 2 enrolling, OASIS study at UNC funded by DoD). [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-4800 (anti-OspA monoclonal antibody)**: Seasonal prevention of Lyme disease – Phase 2 field study planned first half 2027. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-1500 (humanized anti-CD40L mAb)**: Phase 2-ready for prevention of kidney transplant rejection (investigator-initiated study expected mid-2026) and treatment of autoimmune diseases. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-1300 (double-mutant cocaine esterase)**: Phase 2 for cocaine intoxication; FDA Breakthrough Therapy designation. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-2900 (intranasal oxytocin + magnesium)**: For Prader-Willi Syndrome – Orphan Drug and Rare Pediatric Disease designations; Phase 2 planned Q1 2027. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-801 (horsepox live virus vaccine)**: Preclinical – mpox/smallpox protection; Phase 1 expected in 2027. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-4200 (small molecule anti-CD45)**: Broad-spectrum antiviral for biodefense; preclinical, supported by up to $34M DoD contract. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-1700 (TFF2-albumin fusion)**: Preclinical for gastric/colorectal cancer in combination with PD-1 blockade (in-licensed from Columbia University). [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-4900 (Sigma-1 receptor antagonist)**: Preclinical non-opioid analgesic for neuropathic pain. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)

## Market Standing
- **Valuation/Market Cap**: Not publicly available from provided sources (public stock; market cap fluctuates)
- **Key Metric**: Annual Revenue – Not disclosed in provided sources (commercial launch of TONMYA began November 2025; earlier revenue from Zembrace/Tosymra). Total funding rounds not applicable for public company. R&D expenditures detailed in 10-K but not extracted.
- **Notable Investors/Partners**: Almac Pharma Services (commercial supply for TONMYA) [10-K]; U.S. Department of Defense (DTRA contract up to $34M for TNX-4200) [10-K]; University of North Carolina (OASIS study for TNX-102 SL) [10-K]; Columbia University (TNX-1700 in-license) [10-K].
- **Growth Signals**: First FDA approval and launch of internally developed drug TONMYA (Nov 2025); expanding commercial payer coverage (second commercial agreement covering ~52M U.S. lives) [tonixpharma.com]; multiple Phase 2 programs advancing; ownership of two manufacturing facilities (RDC in Frederick, MD and ADC in Dartmouth, MA) [10-K].

## Competitive Advantages
- **First-mover in fibromyalgia**: TONMYA is the first new FDA-approved treatment for fibromyalgia in 15+ years, with a proprietary sublingual formulation that offers differentiated bioavailability and tolerability.
- **Broad, diversified pipeline**: Covers CNS, immunology, infectious disease, and rare disease – reducing single-program risk and providing multiple shots on goal.
- **In-house manufacturing**: Owned R&D Center (Frederick, MD) with BSL-2/3 capability and an Advanced Development Center (Dartmouth, MA) for live-virus vaccine and biologics production (currently decommissioned but ready for reactivation) [10-K].
- **Non-opioid focus**: All analgesic candidates (TONMYA, TNX-4900) are non-opioid, aligning with regulatory and societal trends away from opioids.
- **Government partnerships**: DTRA contract for biodefense work (TNX-4200) provides non-dilutive funding and mission relevance.

## Strategic Focus
- **Grow TONMYA**: Expand commercial coverage, physician adoption, and patient access for fibromyalgia treatment.
- **Advance pipeline**: Initiate or complete Phase 2 studies for TNX-102 SL (MDD, ASD), TNX-4800 (Lyme), TNX-1500 (transplant rejection), TNX-1300 (cocaine intoxication), TNX-2900 (Prader-Willi), and move TNX-801 (mpox/smallpox vaccine) into Phase 1.
- **Pursue strategic business development**: In-licensing, partnerships, and potential acquisitions to augment pipeline and commercial portfolio [10-K].

## Why Work Here
- **Culture**: The company emphasizes a collaborative, inclusive environment where every voice is heard. Mission-driven focus on “listening to patients’ lived experiences” and developing therapies for underserved, complex conditions. [tonixpharma.com/careers](https://www.tonixpharma.com/careers/)
- **Work model**: Information on remote/hybrid policy not publicly available. Office and lab facilities in Berkeley Heights, NJ (HQ), Frederick, MD (R&D Center), and Dartmouth, MA (Advanced Development Center).
- **Team & growth**: Opportunity to work on first-in-class drug launches (TONMYA) and cutting-edge science across multiple therapeutic areas. The company is at a pivotal stage transitioning from pure R&D to a commercial organization, offering varied career pathways.
- **Benefits**: Equal opportunity employer; does not offer visa sponsorship for open positions. [tonixpharma.com/careers](https://www.tonixpharma.com/careers/)
- **Notable perks/engineering culture**: Not detailed, but the science-driven environment with in-house manufacturing and government-funded biodefense work may appeal to researchers and engineers in pharma.

## Sources
1. [tonixpharma.com](https://www.tonixpharma.com/) – Company homepage, mission, product info, lat

_…truncated._

## Other roles at Tonix Pharmaceuticals 

- [Executive Assistant to the Chief Executive Officer](https://feeny.ai/job/executive-assistant-to-the-chief-executive-officer-tonix-pharmaceuticals-q21ne61fzfhr) — Berkeley Heights NJ OR New York, NY
- [Regional Sales Director - California](https://feeny.ai/job/regional-sales-director-california-tonix-pharmaceuticals-california-8thn8v1c8d4r) — California
- [Manager, Financial Reporting](https://feeny.ai/job/manager-financial-reporting-tonix-pharmaceuticals-berkeley-heights-x4szc7r8yxkq) — Berkeley Heights, NJ
- [Senior Associate, Supplier Quality](https://feeny.ai/job/senior-associate-supplier-quality-tonix-pharmaceuticals-north-dartmouth-ma-or-bfw25b7mxm0z) — North Dartmouth MA OR Berkeley Height, NJ
- [Scientist II, In-Vitro & Nonclinical Assay Development](https://feeny.ai/job/scientist-ii-in-vitro-nonclinical-assay-development-tonix-pharmaceuticals-xfw3p1cqhsr3) — Frederick, MD
- [Senior Manager, Information Security](https://feeny.ai/job/senior-manager-information-security-tonix-pharmaceuticals-frederick-md-or-062sk1rtyd2t) — Frederick MD OR Berkeley Heights, NJ
- [​Pharmaceutical Management Rotational Program Associate​](https://feeny.ai/job/pharmaceutical-management-rotational-program-associate-tonix-pharmaceuticals-y27n7mcn4xq0) — Berkeley Heights, NJ
- [Senior Specialist, Corporate Communications](https://feeny.ai/job/senior-specialist-corporate-communications-tonix-pharmaceuticals-berkeley-0rn9ax1k9r08) — Berkeley Heights NJ OR New York, NY
- [Associate Director, Commercial Analytics & Sales Force Effectiveness](https://feeny.ai/job/associate-director-commercial-analytics-sales-force-effectiveness-tonix-21gmwfrwft16) — Berkeley Heights, NJ
- [Senior Manager, Congress Planning & Management](https://feeny.ai/job/senior-manager-congress-planning-management-tonix-pharmaceuticals-berkeley-2r5mphhs7zk2) — Berkeley Heights, NJ